retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial 3: 28.7% Weight Loss (2026) Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $6.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26



















&srotate=0)
